NASDAQ:EVLO Evelo Biosciences (EVLO) Stock Forecast, Price & News $3.63 -0.12 (-3.20%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$3.55▼$3.9050-Day Range$3.63▼$13.3152-Week Range$0.49▼$48.40Volume58,998 shsAverage Volume384,753 shsMarket Capitalization$68.35 millionP/E RatioN/ADividend YieldN/APrice Target$63.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Evelo Biosciences MarketRank™ ForecastAnalyst RatingReduce1.75 Rating ScoreUpside/Downside1,644.7% Upside$63.33 Price TargetShort InterestHealthy2.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$12.50 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($6.70) to ($3.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector537th out of 976 stocksPharmaceutical Preparations Industry244th out of 447 stocks 2.9 Analyst's Opinion Consensus RatingEvelo Biosciences has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $63.33, Evelo Biosciences has a forecasted upside of 1,644.7% from its current price of $3.63.Amount of Analyst CoverageEvelo Biosciences has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.88% of the float of Evelo Biosciences has been sold short.Short Interest Ratio / Days to CoverEvelo Biosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evelo Biosciences has recently decreased by 3.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEvelo Biosciences does not currently pay a dividend.Dividend GrowthEvelo Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EVLO. Previous Next 1.9 News and Social Media Coverage News SentimentEvelo Biosciences has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Evelo Biosciences this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for EVLO on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows4 people have added Evelo Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evelo Biosciences insiders have bought 20,760.45% more of their company's stock than they have sold. Specifically, they have bought $12,499,999.00 in company stock and sold $59,922.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Evelo Biosciences is held by insiders.Percentage Held by Institutions50.69% of the stock of Evelo Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Evelo Biosciences are expected to grow in the coming year, from ($6.70) to ($3.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evelo Biosciences is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evelo Biosciences is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Evelo Biosciences (NASDAQ:EVLO) StockEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Read More EVLO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVLO Stock News HeadlinesAugust 18, 2023 | seekingalpha.comEvelo Biosciences down 39% as 13M share offering beginsAugust 14, 2023 | finanznachrichten.deEvelo Biosciences, Inc.: Evelo Biosciences Announces Second Quarter Financial Results and Recent Business HighlightsOctober 3, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.August 14, 2023 | finance.yahoo.comEvelo Biosciences Announces Second Quarter Financial Results and Recent Business HighlightsAugust 11, 2023 | finance.yahoo.comFMR LLC Acquires Significant Stake in Evelo Biosciences IncJuly 27, 2023 | msn.comMorgan Stanley Maintains Evelo Biosciences (EVLO) Equal-Weight RecommendationJuly 21, 2023 | benzinga.comWhy Are velo Biosciences Stock Is Trading Higher Today?July 21, 2023 | benzinga.comWhy Are Evelo Biosciences Stock Is Trading Higher Today?October 3, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.July 21, 2023 | theglobeandmail.comInstrument Name Evelo Biosciences Inc Instrument Symbol (EVLO-Q)July 12, 2023 | finance.yahoo.comEvelo Biosciences Closes $25.5 Million Private PlacementJuly 11, 2023 | benzinga.comEvelo Biosciences shares are trading higher after the company announced a $25.5 million private placement.July 10, 2023 | marketwatch.comEvelo Biosciences Shares Rise 20% After Private Offering PricesJuly 10, 2023 | msn.comEvelo Biosciences Plans $25.5M Private Placement To Fund Psoriasis Trial, Pay Down DebtJuly 10, 2023 | finance.yahoo.comEvelo Biosciences Announces $25.5 Million Private PlacementJune 30, 2023 | finanznachrichten.deEvelo Biosciences, Inc.: Evelo Biosciences Announces Reverse Stock Split EffectiveJune 29, 2023 | msn.comWhy Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionJune 29, 2023 | finance.yahoo.comEvelo Biosciences Announces Reverse Stock Split EffectiveJune 22, 2023 | finance.yahoo.comEVLO - Evelo Biosciences, Inc.June 20, 2023 | investorplace.comWhy Is Evelo Biosciences (EVLO) Stock Up 51% Today?June 15, 2023 | benzinga.comEvelo Biosciences Granted U.S. Patent #11672834 For "PREBIOTIC COMPOSITIONS AND METHODS OF USE THEREOF FOR MODULATION OF THE MICROBIOME"May 17, 2023 | finance.yahoo.comWhat Makes Evelo Biosciences, Inc. (EVLO) a New Buy StockMay 10, 2023 | finance.yahoo.comEvelo Biosciences Insiders Added US$575k Of Stock To Their HoldingsMay 10, 2023 | finance.yahoo.comEvelo Biosciences Insiders Added US$575k Of Stock To Their Holdings \April 27, 2023 | markets.businessinsider.comEvelo Biosciences (EVLO) Gets a Hold from Morgan StanleyApril 27, 2023 | investorplace.comWhy Is Evelo Biosciences (EVLO) Stock Up 78% Today?April 26, 2023 | finance.yahoo.comFlagship-backed startup makes layoffs for second time in three monthsSee More Headlines Receive EVLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EVLO Company Calendar Last Earnings8/14/2023Today10/03/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EVLO CUSIPN/A CIK1694665 Webwww.evelobio.com Phone(617) 577-0300FaxN/AEmployees66Year FoundedN/APrice Target and Rating Average Stock Price Forecast$63.33 High Stock Price Forecast$100.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+1,644.7%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($18.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,530,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,491.73% Return on Assets-154.51% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.92) per share Price / Book-3.95Miscellaneous Outstanding Shares18,830,000Free Float18,082,000Market Cap$68.35 million OptionableNot Optionable Beta1.71 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Balkrishan Gill Ph.D. (Age 58)Pres, CEO & Director Ms. Marella Thorell (Age 56)CFO, Sr. VP, Principal Financial Officer, Principal Accounting Officer & Treasurer Comp: $530.45kDr. Chun Zhang Ph.D.Chief Technical Operations & Quality OfficerDr. Mark Bodmer Ph.D. (Age 65)Chief Scientific Officer and Pres of R&D Ms. Jessica CotroneVP & Head of CommunicationsMs. Leslie Wardwell-Scott Ph.D.VP and Head of Corp. Devel. & Strategic IntegrationDr. Andrea Itano Ph.D.Head of ResearchDr. Duncan McHale M.D. (Age 56)MBBS, Ph.D., Chief Medical Officer Mr. Douglas MaslinSr. Director & Immunology Clinical LeadMore ExecutivesKey CompetitorsViveon Health AcquisitionNYSE:VHAQKezar Life SciencesNASDAQ:KZRAnebulo PharmaceuticalsNASDAQ:ANEBPyxis OncologyNASDAQ:PYXSProPhase LabsNASDAQ:PRPHView All CompetitorsInsiders & InstitutionsSimba GillSold 1,996 sharesTotal: $7,864.24 ($3.94/share)Jefferies Financial Group Inc.Sold 75,000 shares on 8/14/2023Ownership: 0.000%Credit Suisse AGSold 3,444,895 shares on 8/11/2023Ownership: 3.224%BlackRock Inc.Sold 1,101,855 shares on 8/11/2023Ownership: 0.956%Geode Capital Management LLCSold 579,603 shares on 8/11/2023Ownership: 0.519%View All Insider TransactionsView All Institutional Transactions EVLO Stock - Frequently Asked Questions Should I buy or sell Evelo Biosciences stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" EVLO shares. View EVLO analyst ratings or view top-rated stocks. What is Evelo Biosciences' stock price forecast for 2023? 4 brokers have issued 1-year target prices for Evelo Biosciences' shares. Their EVLO share price forecasts range from $40.00 to $100.00. On average, they anticipate the company's share price to reach $63.33 in the next twelve months. This suggests a possible upside of 1,644.7% from the stock's current price. View analysts price targets for EVLO or view top-rated stocks among Wall Street analysts. How have EVLO shares performed in 2023? Evelo Biosciences' stock was trading at $32.20 at the start of the year. Since then, EVLO stock has decreased by 88.7% and is now trading at $3.63. View the best growth stocks for 2023 here. When is Evelo Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our EVLO earnings forecast. How were Evelo Biosciences' earnings last quarter? Evelo Biosciences, Inc. (NASDAQ:EVLO) issued its quarterly earnings data on Monday, August, 14th. The company reported ($3.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.33) by $0.78. When did Evelo Biosciences' stock split? Evelo Biosciences shares reverse split on Friday, June 30th 2023. The 1-20 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Evelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX). When did Evelo Biosciences IPO? (EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager. What is Evelo Biosciences' stock symbol? Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO." How do I buy shares of Evelo Biosciences? Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Evelo Biosciences' stock price today? One share of EVLO stock can currently be purchased for approximately $3.63. How much money does Evelo Biosciences make? Evelo Biosciences (NASDAQ:EVLO) has a market capitalization of $68.35 million. The company earns $-114,530,000.00 in net income (profit) each year or ($18.18) on an earnings per share basis. How can I contact Evelo Biosciences? Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The official website for the company is www.evelobio.com. The company can be reached via phone at (617) 577-0300 or via email at ir@evelobio.com. This page (NASDAQ:EVLO) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.